Our site uses cookies to make navigation as functional as possible, including "third party" cookies and "profiling cookies" designed to tailor on-line contents to suit the preferences expressed while surfing the internet. Should you wish to receive more information, or deny your consent to some or all cookies, click here. If you proceed browsing this website, you will be consenting to the use of all cookies.

MEN1309

Monoclonal human antibody conjugated to a toxin against B-Non Hodgkin lymphoma and solid tumors such a subtype of breast cancer.

ONCOLOGY

Logo Shuttle 1309


Current development phase: Phase I

preclinical
Phase I
Phase ii
Phase iii
preregistration

MEN1309 is the second monoclonal antibody to be developed in the collaboration between Menarini and OBT (Oxford BioTherapeutics).
MEN 1309 is a human monoclonal antibody conjugated to a potent cytotoxic agent, maytansin derivative, against a membrane antigen, CD205, which is over-expressed in many tumors such non-Hodgkin lymphoma (NHL) and solid tumors such a subtype of breast cancer 

Antibodies conjugate to a toxin belong to a new class of biopharmaceuticals for the treatment of tumors that act via an innovative mechanism called ADC (Antibody Drug Conjugate).

Through this mechanism, MEN1309 exerts a potent and selective cytotoxic activity on tumor cells.

The biotechnological process for the production of MEN1309 has been developed at Menarini Biotech in Pomezia. 

MEN1309 has demonstrated an excellent anti-tumoral activity in different experimental xenograft models.
Non-clinical safety studies to support the first in human study have been completed. A phase I clinical trial in oncological patients is active in 4 European Countries (Belgium,Spain, United Kingdom, Italy) to identify the Maximum Tolerated Dose of the MEN1309.


VISIT OUR CLINICAL TRIALS DATABASE

 

 

THERAPEUTIC AREAS

Discover all of Menarini's products marketed in Italy. Read More »

DIAGNOSTICS

 

Advanced Technology

READ MORE »

THE MENARINI GROUP

Discover the leading Italian pharmaceutical company in the world. Read More »

MENARINI PILLS OF ART

Concession granted by Italian Ministry for Cultural Heritage and Activities Read more